Literature DB >> 22005532

Mitotic inhibitors.

Edward B Garon1, Steven M Dubinett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22005532      PMCID： PMC3812544          DOI： 10.1097/01.JTO.0000407560.61287.3f

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

Review 1.  Kinesin motor proteins as targets for cancer therapy.

Authors:  Dennis Huszar; Maria-Elena Theoclitou; Jeffrey Skolnik; Ronald Herbst
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

2.  Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Authors:  Kazuki N Sugahara; Tambet Teesalu; Priya Prakash Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Daniel R Greenwald; Erkki Ruoslahti
Journal:  Science       Date:  2010-04-08       Impact factor: 47.728

Review 3.  Shared and separate functions of polo-like kinases and aurora kinases in cancer.

Authors:  Susanne M A Lens; Emile E Voest; René H Medema
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

4.  The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth.

Authors:  Mary Ann Jordan; Kathryn Kamath; Tapas Manna; Tatiana Okouneva; Herbert P Miller; Celia Davis; Bruce A Littlefield; Leslie Wilson
Journal:  Mol Cancer Ther       Date:  2005-07       Impact factor: 6.261

5.  Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel.

Authors:  C G Milross; K A Mason; N R Hunter; W K Chung; L J Peters; L Milas
Journal:  J Natl Cancer Inst       Date:  1996-09-18       Impact factor: 13.506

6.  SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients.

Authors:  Neil Desai; Vuong Trieu; Bruno Damascelli; Patrick Soon-Shiong
Journal:  Transl Oncol       Date:  2009-05       Impact factor: 4.243

7.  Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

Authors:  Johan Vansteenkiste; Primo N Lara; Thierry Le Chevalier; Jean-Luc Breton; Philip Bonomi; Alan B Sandler; Mark A Socinski; Catherine Delbaldo; Brent McHenry; David Lebwohl; Ronald Peck; Martin J Edelman; Mark Edelman
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.